Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
The Future Of Inflammation: The Inflammasome And Beyond - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
The Future Of Inflammation: The Inflammasome And Beyond
Insights Citeline
Nov 13, 2024
The Future Of Inflammation: The Inflammasome And Beyond
Related Posts
Post navigation
Previous Post
Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson’s Breakthroughs
Next Post
GT-02287 seen to safely enter brain in early Parkinson’s clinical trial
Latest Articles
Clear Filters
July 1, 2026
Parkinson’s pipeline pushes beyond dopamine
https://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopamine?utm_term=profiles.biocentury.com
Read More
June 30, 2026
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com
https://in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234
Read More
June 11, 2026
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
https://european-biotechnology.com/latest-news/scenic-biotech-joins-michael-j-fox-lrrk2-consortium-with-a-novel-lysosomal-bet-on-parkinsons/
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
